|Bid||0.8206 x 1300|
|Ask||0.8347 x 3000|
|Day's range||0.7602 - 0.8687|
|52-week range||0.3460 - 4.7700|
|Beta (5Y monthly)||2.31|
|PE ratio (TTM)||N/A|
|Earnings date||07 Nov 2023 - 13 Nov 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||1.35|
Key Insights Canopy Growth's Annual General Meeting to take place on 25th of September Total pay for CEO David Klein...
(Bloomberg) -- A surge in shares of cannabis companies has saddled short sellers with more than $105 million in losses this year, but that hasn’t stopped traders from betting against the sector.Most Read from BloombergDebris Spotted in Search for Missing US F-35 Fighter JetIndia, Canada Trade Diplomatic Blows Over Murder AllegationsVegas’ Newest Resort Is a $3.7 Billion Palace, 23 Years in the MakingHow Auto Executives Misread the UAW Ahead of Historic StrikeXi’s Missing Defense Chief Opens Door
Following urgings by the U.S. Department of Health & Human Services, DEA officials could reclassify marijuana's drug status to that of a Schedule III substance. Curaleaf (CURLF) CEO Matt Darin joins Yahoo Finance Live to discuss what new regulation could mean for the cannabis industry and certain banking system oversights. "We think this is going to be a massive catalyst," Darin describes. "The biggest impact from a financial standpoint will be the removal of the draconian 280E section of the tax code that has really become untenable for our regulated industry." Darin outlines the higher tax rates cannabis distributors incur, emphasizing the fact that the U.S. government "collects more state taxes from cannabis than they do from alcohol." He comments on the outlook and expansion of the cannabis industry on marijuana's potential reclassification.